Soleus Capital Management L.P. Has $31.95 Million Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Soleus Capital Management L.P. raised its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 11.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,494,420 shares of the company's stock after purchasing an additional 150,755 shares during the quarter. Jasper Therapeutics comprises 2.0% of Soleus Capital Management L.P.'s portfolio, making the stock its 16th largest holding. Soleus Capital Management L.P. owned about 9.96% of Jasper Therapeutics worth $31,951,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Rhumbline Advisers boosted its position in shares of Jasper Therapeutics by 12.6% during the 4th quarter. Rhumbline Advisers now owns 14,761 shares of the company's stock valued at $316,000 after purchasing an additional 1,652 shares in the last quarter. Barclays PLC boosted its holdings in Jasper Therapeutics by 13.6% during the fourth quarter. Barclays PLC now owns 18,334 shares of the company's stock worth $392,000 after buying an additional 2,188 shares in the last quarter. Wellington Management Group LLP grew its position in Jasper Therapeutics by 13.9% in the fourth quarter. Wellington Management Group LLP now owns 27,069 shares of the company's stock worth $579,000 after buying an additional 3,310 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock valued at $159,000 after buying an additional 3,828 shares in the last quarter. Finally, Rock Springs Capital Management LP lifted its position in shares of Jasper Therapeutics by 0.9% during the 4th quarter. Rock Springs Capital Management LP now owns 463,088 shares of the company's stock valued at $9,901,000 after acquiring an additional 4,000 shares during the last quarter. Institutional investors own 79.85% of the company's stock.

Jasper Therapeutics Stock Up 1.0%

Shares of Jasper Therapeutics stock traded up $0.05 on Thursday, hitting $4.87. 142,022 shares of the company traded hands, compared to its average volume of 293,005. Jasper Therapeutics, Inc. has a 12-month low of $3.13 and a 12-month high of $26.84. The company has a 50-day moving average price of $4.57 and a 200 day moving average price of $10.66. The company has a market cap of $73.16 million, a PE ratio of -1.03 and a beta of 2.74.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.24). Equities research analysts anticipate that Jasper Therapeutics, Inc. will post -4.47 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. UBS Group decreased their target price on Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Oppenheimer decreased their price target on Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $62.22.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.